Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) had its target price raised by stock analysts at Barclays from $18.00 to $22.00 in a research report issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price target suggests a potential upside of 26.22% from the company’s current […]
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $21.00 at The Goldman Sachs Group theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down on Disappointing Earnings themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript February 28, 2024 Iovance Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.45 EPS, expectations were $-0.44. Iovance Biotherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to […]